Clinical Efficacy Of TURP Combined With MAB In The Treatment Of Prostate Cancer

Objective: To evaluate the clinical efficacy and tolerability of transurethral resection of the prostate(TURP)combined with maximal androgen blockade(MAB)and MAB alone in the treatment of prostate cancer.To analyze the difference between the two treatments in the different clinical characteristics and the improvement of urinary symptoms of TURP in prostate cancer patients.Methods: One hundred and forty-seven patients treated by MAB(surgical castration plus antiandrogen therapy)from Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Medicine from January 2010 to December 2015 were enrolled in the current study.Of these,52 patients with TURP were treated as cytodeductive therapy defiend as Group A,97 cases of MAB therapy was defined as group B.The effect of TURP on prostate cancer was analyzed by Kaplan-Meier survival curve and other statistical methods were used to review the overall survival time,PSA-free progression time,response to endocrine therapy and urinary symptoms in both groups.Results: The median overall survival time of TURP combined with MAB treatment was 47 months,while the MAB therapy group was 45months(P = 0.651).The median PSA-free progression survival of Group A was 24 months,and the median PSA-free progression survival of Group B was 20 months(P=0.038).At 3-month,TURP combined with MAB therapy was better in IPSS and Qo L than in the MAB alone treated patients(P =0.001,P = 0.001),but at 12 month both IPSS and Qo L were not statistically different(P =0.336,P = 0.431).The response rates of TURP combined with MAB and MAB were 48.1% and 45.2%,(P =0.744).No serious complications were observed in the application of TURP as the treatment for prostate cancer.Conclusion: TURP combined with MAB therapy can prolong the PSA-free progression survival time of prostate cancer,but no significant prolongation of overall survival time.TURP combined with MAB can improve the symptoms of urinary obstruction in patients with prostate cancer and does not increase the incidence of severe complications.TURP remains to be further studied in improving the response of prostate cancer to endocrine therapy.